Skip to content
Screener

Vertex Pharmaceuticals VRTX Business Segments — Product revenues, net

Similar metrics at other companies

Collegium Pharmaceutical, Inc. logo
COLLSegment — Product revenues, net
$199.88M+6.3%
Insmed logo
INSMInternational — Product revenues, net
$46.75M+20.7%
Insmed logo
INSMUS — Product revenues, net
$378.74M+451%
Insmed logo
INSMBRINSUPRI — Product revenues, net
$309.17M
Collegium Pharmaceutical, Inc. logo
COLLAzstarys — Product revenues, net
$12.91M
Collegium Pharmaceutical, Inc. logo
COLLBelbuca — Product revenues, net
$57.67M+9.6%

Other financials

Income statement

See full
Revenue$3.3B+12.5%
Gross profit$2.8B+11.2%
Operating income$1.2B+8.3%
Net income$1.1B+6.5%
EPS (diluted)$4.31+8.0%

Balance sheet

See full
Cash & equivalents$7.9B+57.6%
Total debt$2.0B+29.5%
Total equity$20.2B+17.9%
Total assets$27.4B+14.1%

Cash flow

See full
Operating cash flow$1.4B+74.4%
CapEx$133.4M+228%
Free cash flow$1.3B+66.4%

Valuation

See full
Market cap$122.68B+24.1%
Enterprise value$116.81B+22.4%
P/E27.9×
P/S9.8×+1.1×

Profitability

See full
Gross margin86%-0.1pp
Operating margin38%
Net margin35%
FCF margin30.4%+20.2pp

Returns & leverage

See full
Return on equity23.5%
Debt / equity0.1×0.0×
Current ratio3.2×+0.7×

Where this comes from

Reported directly by Vertex Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000875320-26-000173
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
(in millions)
Total revenues$2,986.9$2,770.2
Costs and expenses:
Cost of sales - products160.2130.6
Cost of sales - royalty232.6232.4
Research expenses205.0206.1
Development expenses756.6773.6
Acquired in-process research and development expenses0.519.8

Item 1. Financial Statements (unaudited)

FAQ

What is Vertex Pharmaceuticals's business segments — product revenues, net?
Vertex Pharmaceuticals (VRTX) reported business segments — product revenues, net of $2.99B in Q1 2026.
How has Vertex Pharmaceuticals's business segments — product revenues, net changed year-over-year?
Vertex Pharmaceuticals's business segments — product revenues, net increased by 7.8% year-over-year, from $2.77B to $2.99B.
What is the long-term trend for Vertex Pharmaceuticals's business segments — product revenues, net?
Over 3 years (2022 to 2025), Vertex Pharmaceuticals's business segments — product revenues, net has grown at a 10.4% compound annual growth rate (CAGR), from $8.93B to $12B.
What does business segments — product revenues, net mean?
Represents the total revenue generated from the sale of pharmaceutical products after accounting for returns, rebates, and discounts. This is the primary indicator of market demand and commercial success for the company's therapeutic portfolio.

Ask your AI about Vertex Pharmaceuticals's business segments — product revenues, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude